Pigeon Genetics [04] Recessive Red
Autosomal recessive gene which will turn anyone of the three base colors (Click #39;Show more #39;) (seen in video 01) to a solid red all over. However other genes ...

By: FlyingTipplers

View post:
Pigeon Genetics [04] Recessive Red - Video

Recommendation and review posted by Bethany Smith

Clinical trial starts to restore vision loss using gene therapy
Sat, Oct 12: A medical team at the University of Alberta is pioneering a potentially life changing procedure that could improve or restore vision loss. Globa...

By: GlobalToronto

Go here to see the original:
Clinical trial starts to restore vision loss using gene therapy - Video

Recommendation and review posted by Bethany Smith

Oct. 16, 2013 Johns Hopkins scientists have developed new drugs that -- at least in a laboratory dish -- appear to halt the brain-destroying impact of a genetic mutation at work in some forms of two incurable diseases, amyotrophic lateral sclerosis (ALS) and dementia.

They made the finding by using neurons they created from stem cells known as induced pluripotent stem cells (iPS cells), which are derived from the skin of people with ALS who have a gene mutation that interferes with the process of making proteins needed for normal neuron function.

"Efforts to treat neurodegenerative diseases have the highest failure rate for all clinical trials," says Jeffrey D. Rothstein, M.D., Ph.D., a professor of neurology and neuroscience at the Johns Hopkins University School of Medicine and leader of the research described online in the journal Neuron. "But with this iPS technology, we think we can target an exact subset of patients with a specific mutation and succeed. It's individualized brain therapy, just the sort of thing that has been done in cancer, but not yet in neurology."

Scientists in 2011 discovered that more than 40 percent of patients with an inherited form of ALS and at least 10 percent of patients with the non-inherited sporadic form have a mutation in the C9ORF72 gene. The mutation also occurs very often in people with frontotemporal dementia, the second-most-common form of dementia after Alzheimer's disease. The same research appeared to explain why some people develop both ALS and the dementia simultaneously and that, in some families, one sibling might develop ALS while another might develop dementia.

In the C9ORF72 gene of a normal person, there are up to 30 repeats of a series of six DNA letters (GGGGCC); but in people with the genetic glitch, the string can be repeated thousands of times. Rothstein, who is also director of the Johns Hopkins Brain Science Institute and the Robert Packard Center for ALS Research, used his large bank of iPS cell lines from ALS patients to identify several with the C9ORF72 mutation, then experimented with them to figure out the mechanism by which the "repeats" were causing the brain cell death characteristic of ALS.

In a series of experiments, Rothstein says, they discovered that in iPS neurons with the mutation, the process of using the DNA blueprint to make RNA and then produce protein is disrupted. Normally, RNA-binding proteins facilitate the production of RNA. Instead, in the iPS neurons with the C9ORF72 mutation, the RNA made from the repeating GGGGCC strings was bunching up, gumming up the works by acting like flypaper and grabbing hold of the extremely important RNA binding proteins, including one known as ADARB2, needed for the proper production of many other cellular RNAs. Overall, the C9ORF72 mutation made the cell produce abnormal amounts of many other normal RNAs and made the cells very senstive to stress.

To counter this effect, the researchers developed a number of chemical compounds targeting the problem. This compound behaved like a coating that matches up to the GGGGCC repeats like velcro, keeping the flypaper-like repeats from attracting the bait, allowing the RNA-binding protein to properly do its job.

Rothstein says Isis Pharmaceuticals helped develop many of the studied compounds and, by working closely with the Johns Hopkins teams, could begin testing it in human ALS patients with the C9ORF72 mutation in the next several years. In collaboration with the National Institutes of Health, plans are already underway to begin to identify a group of patients with the C9ORF72 mutation for future research.

Rita Sattler, Ph.D., an assistant professor of neurology at Johns Hopkins and the co-investigator of the study, says without iPS technology, the team would have had a difficult time studying the C9ORF72 mutation. "Typically, researchers engineer rodents with mutations that mimic the human glitches they are trying to research and then study them," she says. "But the nature of the multiple repeats made that nearly impossible." The iPS cells did the job just as well or even better than an animal model, Sattler says, in part because the experiments could be done using human cells.

"An iPS cell line can be used effectively and rapidly to understand disease mechanisms and as a tool for therapy development," Rothstein adds. "Now we need to see if our findings translate into a valuable treatment for humans."

See the original post:
'Individualized' therapy for the brain targets specific gene mutations causing dementia, ALS

Recommendation and review posted by Bethany Smith

Public release date: 16-Oct-2013 [ | E-mail | Share ]

Contact: Stephanie Desmon sdesmon1@jhmi.edu 410-955-8665 Johns Hopkins Medicine

Johns Hopkins scientists have developed new drugs that at least in a laboratory dish appear to halt the brain-destroying impact of a genetic mutation at work in some forms of two incurable diseases, amyotrophic lateral sclerosis (ALS) and dementia.

They made the finding by using neurons they created from stem cells known as induced pluripotent stem cells (iPS cells), which are derived from the skin of people with ALS who have a gene mutation that interferes with the process of making proteins needed for normal neuron function.

"Efforts to treat neurodegenerative diseases have the highest failure rate for all clinical trials," says Jeffrey D. Rothstein, M.D., Ph.D., a professor of neurology and neuroscience at the Johns Hopkins University School of Medicine and leader of the research described online in the journal Neuron. "But with this iPS technology, we think we can target an exact subset of patients with a specific mutation and succeed. It's individualized brain therapy, just the sort of thing that has been done in cancer, but not yet in neurology."

Scientists in 2011 discovered that more than 40 percent of patients with an inherited form of ALS and at least 10 percent of patients with the non-inherited sporadic form have a mutation in the C9ORF72 gene. The mutation also occurs very often in people with frontotemporal dementia, the second-most-common form of dementia after Alzheimer's disease. The same research appeared to explain why some people develop both ALS and the dementia simultaneously and that, in some families, one sibling might develop ALS while another might develop dementia.

In the C9ORF72 gene of a normal person, there are up to 30 repeats of a series of six DNA letters (GGGGCC); but in people with the genetic glitch, the string can be repeated thousands of times. Rothstein, who is also director of the Johns Hopkins Brain Science Institute and the Robert Packard Center for ALS Research, used his large bank of iPS cell lines from ALS patients to identify several with the C9ORF72 mutation, then experimented with them to figure out the mechanism by which the "repeats" were causing the brain cell death characteristic of ALS.

In a series of experiments, Rothstein says, they discovered that in iPS neurons with the mutation, the process of using the DNA blueprint to make RNA and then produce protein is disrupted. Normally, RNA-binding proteins facilitate the production of RNA. Instead, in the iPS neurons with the C9ORF72 mutation, the RNA made from the repeating GGGGCC strings was bunching up, gumming up the works by acting like flypaper and grabbing hold of the extremely important RNA binding proteins, including one known as ADARB2, needed for the proper production of many other cellular RNAs. Overall, the C9ORF72 mutation made the cell produce abnormal amounts of many other normal RNAs and made the cells very senstive to stress.

To counter this effect, the researchers developed a number of chemical compounds targeting the problem. This compound behaved like a coating that matches up to the GGGGCC repeats like velcro, keeping the flypaper-like repeats from attracting the bait, allowing the RNA-binding protein to properly do its job.

Rothstein says Isis Pharmaceuticals helped develop many of the studied compounds and, by working closely with the Johns Hopkins teams, could begin testing it in human ALS patients with the C9ORF72 mutation in the next several years. In collaboration with the National Institutes of Health, plans are already underway to begin to identify a group of patients with the C9ORF72 mutation for future research.

See the original post here:
'Individualized' therapy for the brain targets specific gene mutations causing dementia and ALS

Recommendation and review posted by Bethany Smith

"5k, Ballet, and a Spinal Cord Injury" From the Authors #39; Perspectives
Take a look at how the authors feel about their book!

By: ST Jen

Read more here:
"5k, Ballet, and a Spinal Cord Injury" From the Authors' Perspectives - Video

Recommendation and review posted by sam

AUSTIN, Texas--(BUSINESS WIRE)--

Altogen Labs, a CRO laboratory located in Austin, Texas (USA), provides preclinical pharmacology and oncology contract research services for pharmaceutical, biotechnology, and academic research institutions worldwide. Company scientists bring years of experience and expertise in life science and drug discovery research services.

Altogen Labs offers GLP-compliant research and development services that include preclinical trials to assess the toxicity and pharmacological activity of investigative new drugs, PK and PD studies, tumor xenograft models, ELISA assay development, stable cell line generation, and other in vitro and in vivo pharmacology/toxicology research services. To accelerate oncology drug development Altogen Labs offers proof of concept and mechanism of action studies, developing strategies for more rapid IND regulatory approval.

By offering RNA Interference (RNAi) gene silencing services, Altogen Labs provide clients A-to-Z complete solution for development of RNAi therapeutics. Gene silencing in vivo and in vitro services include the design and development of functional siRNA, shRNA, and miRNA oligonucleotides, synthesis and liposome encapsulation, gene targeting, siRNA transfection and tissue-targeted RNAi delivery, development of stable RNAi cell lines, gene expression analysis and quantification of mRNA knockdown, in vivo biodistribution and xenograft testing.

About Altogen Labs

Altogen Labs is a contract research organization (CRO) providing laboratory research and development services. Altogen Labs services include preclinical research studies, oncology CRO, toxicology IND studies, in vivo biodistribution and xenograft models. Altogen Labs is headquartered in Austin, TX. For more information, please visit http://www.altogenlabs.com or call us 512-433-6177.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131015006857/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50729255&lang=en

Read more from the original source:
Altogen Labs Provides Biology CRO Contract Research Services to Accelerate Preclinical and Oncology Research Studies

Recommendation and review posted by Bethany Smith

Kathryn Coldren

Joe Peters, associate professor of microbiology, is a founding member of the R3 group, which was started 10 years ago as a forum to discuss mutual interests among an interdisciplinary group of scientists.

Once a month, every month, for the past 10 years, an assortment of scientists from all corners of the university have been coming together to collaborate around one topic central to all their research: DNA replication, recombination and repair.

The R3 Group has representatives from 10 core labs among its regular members, in the Departments of Biomedical Sciences, Chemistry and Chemical Biology, Plant Breeding and Genetics, Microbiology, and Molecular Biology and Genetics. Some work with bacteria, others with plants or animals, but all of the scientists explore the processes that help control genetic stability.

The group has welcomed more than 80 speakers to its monthly meetings, and it recently hosted three prominent guests Tony Huang of New York University, Anne Villeneuve of Stanford University and Graham Walker of the Massachusetts Institute of Technology as part of a 10th anniversary celebration Oct. 3-4.

More than 200 people from Cornell and other institutions gathered in the Biotechnology Building and Weill Hall to hear about a range of research into the fundamental science of how all organisms deal with the enormous task of replicating and segregating their genomes with minimal errors.

This basic science is critical in understanding the genetic basis of diseases, primarily birth defects and cancer, said John Schimenti, director of the Center for Vertebrate Genomics at the College of Veterinary Medicine, one of the organizers of the conference.

By studying DNA replication and cellular responses to carcinogen damage, Walker has gained insights into an emerging issue in cancer treatment: chemotherapy resistance. During his keynote address, the MIT biology professor explained how his discoveries about translesion polymerases could be used to combat this resistance and improve treatment. He also shared his research into replication processes related to stress responses and oxygen use in bacteria, which could have an impact on our use of other medicines, such as antibiotics and antimicrobials.

Walkers presentation provided great examples of how research can move from simple-model systems like bacteria and yeast into more complex animal and human systems, said Joe Peters, a founding member of the R3 group.

The associate professor of microbiology is the one to whom members turn with questions about basic bacterial systems; he, in turn, is often inspired by their approaches.

Here is the original post:
Gene scientists celebrate 10 years of collaboration

Recommendation and review posted by Bethany Smith

New GE techniques slipping under the radar?

A new gene-splitting technique must be defined as genetic engineering, says the Soil & Health Association. If not, more new techniques like it may be used in crops, food and other products without our knowledge, and with unknown consequences. Zinc finger nuclease involves splitting DNA strands so that genetic material may be inserted or removed.

There is a raft of new technologies being developed that are the next wave of genetic engineering, says Marion Thomson, co-chair of Soil & Health Organic NZ. These new technologies must be thoroughly and independently scrutinised and the precautionary principle applied. Otherwise, its an uncontrolled experiment that could have adverse effects for people, animals and the environment.

The Soil & Health Association commends the Sustainability Council for challenging a decision by the Environmental Protection Authority (EPA) that zinc finger nuclease is not genetic engineering. The EPA committee that made the decision went against staff advice. The case will now be heard in the High Court in Wellington in November.

ends

Scoop Media

More:
New GE techniques slipping under the radar?

Recommendation and review posted by Bethany Smith

Oct. 15, 2013 Scientists at the University of Washington have used genetic engineering to identify a population of neurons that tell the brain to shut off appetite. Their study, "Genetic identification of a neural circuit that suppresses appetite," was published Oct. 13 in Nature.

To identify these neurons, or cells that process and transmit information in the brain, researchers first considered what makes an animal lose its appetite. There are a number of natural reasons, including infection, nausea, pain or simply having eaten too much already.

Nerves within the gut that are distressed or insulted send information to the brain through the vagus nerve. Appetite is suppressed when these messages activate specific neurons -- ones that contain CGRP, (calcitonin gene-related peptide) in a region of the brain called the parabrachial nucleus.

In mouse trials, researchers used genetic techniques and viruses to introduce light-activatable proteins into CGRP neurons. Activation of these proteins excites the cells to transmit chemical signals to other regions of the brain. When they activated the CGRP neurons with a laser, the hungry mice immediately lost their appetite and walked away from their liquid diet (Ensure); when the laser was turned off, the mice resumed drinking the liquid diet.

"These results demonstrate that activation of the CGRP-expressing neurons regulates appetite. This is a nice example of how the brain responds to unfavorable conditions in the body, such as nausea caused by food poisoning" said Richard Palmiter, UW professor of biochemistry and investigator of the Howard Hughes Medical Institute.

Using a similar approach, neurons in other brain regions have been identified that can stimulate the appetite of mice that are not hungry. Researchers hope to identify the complete neural circuit (wiring diagram) in the brain that regulates feeding behavior. By identifying these neural circuits, scientists may be able to design therapies that promote or decrease appetite.

View original post here:
Genetic identification of neural circuit that suppresses appetite

Recommendation and review posted by Bethany Smith

Newswise BIRMINGHAM, Ala. The University of Alabama at Birmingham (UAB) today announced that Illumina Inc. has licensed the rights to a DNA sequencing technology developed by a UAB microbiologist and a University of Washington physicist.

The patent-licensing deal revolves around nanopores first studied as potential chinks in the armor of the tuberculosis bacteria, but now part of efforts to make sequencing even faster and cheaper.

Sequencing reveals genetic variations, which partly determine each persons risk for many diseases as well as which drugs will work for him or her. Cancer centers are already sequencing tumors in search of variations that make some resistant to chemotherapy. Global sequencing studies seek to find the genetic contributors to conditions such as autism and diabetes.

Widespread access to genetic information will improve medical care worldwide; but in order to become part of daily, personalized medicine, DNA sequencing methods will need to become faster and cheaper, said Michael Niederweis, Ph.D., a microbiology professor in the UAB School of Medicine and one of two researchers who developed the technology. Our nanopore technology promises to achieve that, and we believe Illumina can transform our experimental system into a pioneering commercial technology.

While the terms of the deal are confidential, the license gives Illumina exclusive worldwide rights to develop and market the nanopore DNA sequencing technology developed by Jens Gundlach, Ph.D., a professor of physics at the University of Washington (UW), Niederweis and their teams. The technology is protected by pending patent applications co-owned by the UAB Research Foundation and UW.

Many companies and universities are looking at the potential of nanopore technology, but the technology developed by Drs. Niederweis and Gundlach is among the most promising, said Christian Henry, senior vice president and general manager of Illuminas Genomics Solutions business.

Path to a simpler sequencing technology In every human cell, the blueprint for the body is encoded in chains of molecules called deoxyribonucleic acids or DNA. DNA chains are, in turn, composed of nucleotides, each of which includes one of four bases adenine, thymine, guanine or cytosine. These bases serve as the letters making up the genetic code, and sequencing methods determine their precise order.

It took The Human Genome Project 10 years and cost $3 billion to sequence the first complete set of genetic information, or genome, for one human, with the results announced in 2003. That same feat today takes a couple of days and costs about $4,000. Dramatic improvements in template preparation, sequencing strategies and image processing made this astounding leap possible in recent years, but DNA sequencing has yet to cross the threshold that will make it part of everyday medicine: to decode a patients genome within hours for less than a thousand dollars.

Many labs are looking for ways to replace the current processes with simpler, cheaper ones. One such approach is nanopore sequencing, which employs a pore just large enough for a DNA strand to slip through.

As the molecule passes through the pore, it partially blocks an electrical current. This enables each of the four DNA bases to generate a unique electrical signal and allows the system to identify the sequence. Bacteria evolved to have such pores in their outer membranes because they efficiently let in nearby nutrients sugars, phosphates and amino acids that happen to be about the same size as a single DNA nucleotide.

Read more:
Licensing Deal Marks Coming of Age for UAB-UW Nanopore Sequencing Technology

Recommendation and review posted by Bethany Smith

Public release date: 14-Oct-2013 [ | E-mail | Share ]

Contact: Aeron Haworth aeron.haworth@manchester.ac.uk 44-161-275-8387 University of Manchester

The Manchester Academic Health Science Centre (MAHSC) has formed a partnership with the Peking University Health Sciences Centre to establish an international centre of excellence in genetic medicine.

The new Peking-Manchester Centre for Genomic Medicine, announced by British Chancellor George Osborne in Beijing today (Monday), will comprise three separate but interdependent research facilities the International Centre for Rare Diseases, the Centre for Cancer Genetics, and the Joint Clinical Trials Facility.

MAHSC's involvement is being led by the Manchester Centre for Genomic Medicine, an integrated centre bringing together University of Manchester researchers and Central Manchester NHS Foundation Trust's clinical services, to form a world leader in genetic and genomic medicine for research into inherited diseases and delivery of services to families with inherited disorders.

Speaking at Peking University, the Chancellor, who is in China to promote UK business and encourage Chinese investors to choose Britain, said: "I am delighted to announce here the establishment of a new partnership between Peking University and Manchester University in the UK with the creation of a new joint centre for genomic medicine. Here, in the oldest and most prestigious medical school in China, let us work together on the medicines of tomorrow.

"This partnership will, I hope, give even more of you the chance to come to Britain and to study there. We already have 130,000 Chinese students, like you, studying in Britain I want more of you to come There is no limit to the number of Chinese [students] who can study in Britain."

Dean and Vice-President of the University of Manchester's Faculty of Medical and Human Sciences and Director of MAHSC, Professor Ian Jacobs, who is participating in the government-led visit, said: "This is an exciting partnership between MAHSC and our colleagues in Beijing. It will lead to important health and research benefits in the rapidly developing field of genetics to benefit the people of both countries as well as having a global impact. The planned work will draw on populations of up to 50 million individuals to harness next-generation genetic technology for patient benefit.

"The joint venture will contribute to the further development of the research strength of the Manchester Academic Health Science Centre and advance Manchester's international reputation as a world leader in personalised cancer medicine, while improving care and diagnosis for many people here and in China."

The Peking University Health Sciences Centre (PUHSC) is the oldest Western medical school in China, ranked first in the country for research and training. As part of the collaboration, six senior geneticists from the Manchester Centre for Genomic Medicine will travel to Beijing this week to deliver a training course for more than 300 health professionals and scientists at PUHSC.

Read the original here:
UK Chancellor announces Sino-British health partnership

Recommendation and review posted by Bethany Smith

Carilion Clinic Living: Breast Cancer and Genetics
Thuy Vu, a certified genetics counselor with Carilion Clinic in Roanoke, Va. discusses how your family medical history can play a role in the risk for breast...

By: Carilion Clinic

See more here:
Carilion Clinic Living: Breast Cancer and Genetics - Video

Recommendation and review posted by Bethany Smith

Race and Genetics in Bodybuilding- Response to Nick Wright
Responding to racial comments made regarding bodybuilding and athletics based on my experience as a bi-racial person. OFFICIAL SITE: http://yungmuscle.com/ F...

By: YungMuscleOfficialTV

Go here to read the rest:
Race and Genetics in Bodybuilding- Response to Nick Wright - Video

Recommendation and review posted by Bethany Smith

SOUR SECRET - DNA Genetics - Voyagers Coffeeshop - Amsterdam Weed Review
http://andrew.pyrah.net Thanks for watching! COMMENT and LIKE if you enjoyed the video and SUBSCRIBE to see my new videos as they are released. This video is...

By: Andrew Pyrah

View original post here:
SOUR SECRET - DNA Genetics - Voyagers Coffeeshop - Amsterdam Weed Review - Video

Recommendation and review posted by Bethany Smith

Analyzing Is Magic: The Problem With Pegasi Genetics
Something that I noticed. Thought I would share. With apologies to Tom Petty. Anyway, what do you think of this! Comments and questions below! ... OC Faces: ...

By: ILoveKimPossibleAlot

Here is the original post:
Analyzing Is Magic: The Problem With Pegasi Genetics - Video

Recommendation and review posted by Bethany Smith

GENETICS Australia says shareholders will benefit from the sale of its retail and services businesses.

GA sold these operations in Gippsland to Herd Improvement Co-operative yesterday and its Western District operations to Northern Herd Development Co-operative.

It said the sales would achieve benefits similar to a proposed merger with HICO and provide a "necessary rationalisation of the herd improvement sector".

Genetics Australia chairman Ross Gordon said a merger between HICO and GA was not off the table, but the costs and time involved, especially in the tough dairying climate, forced the co-operatives to look at another path to rationalisation.

"We had to cut some serious cost down," Mr Gordon said.

"What we were doing with the merger would take quite a bit more money ... and there wasn't any guarantee we would get it over the line and then meet the thresholds (for tax).

"There was a potential $100,000 bill for capital gains tax and there is not that sort of money in the industry ... to give away."

The move ensures a lab to test herd recording results remains in each Victorian dairy region, while GA will return to its original business of production, import and marketing of semen and related products.

"It's a good win for shareholders, they still get choices and there will be a lab in each region," Mr Gordon said.

"It's consolidation of the herd improvement industry with the two key co-operatives."

More here:
Genetics Australia sells off divisions

Recommendation and review posted by Bethany Smith

ORCHARD, Texas, Oct. 15, 2013 (GLOBE NEWSWIRE) -- Exclusive Genetics, a leader and innovator in the bucking bull industry, is out-of-the-gate with exciting investment opportunities for enthusiasts nationwide. No ranch, no truck, no trailer, no experience necessary - bucking bulls are not just for ranchers and cowboys anymore. With the explosive growth of this traditionally western lifestyle sport, the bucking bull industry is now capturing the attention of a completely new group of customers - business owners, corporate executives and professionals. Exclusive Genetics gives these new thrill-seekers the ability to experience high quality, high payout events and at the same time enjoy great hospitality and fellowship.

With investors including several CEOs of major corporations and the Manager of a Major League Baseball team, Exclusive Genetics caters to the needs of the first-time client by developing events that fit the investors' interests. The cornerstone of EG's program is the Million Dollar Bucking Bull Championship for 2-year-old bulls. The event's $1,000,000 payout and $500,000 check to the top bull makes the event the most lucrative and highly respected in the entire bucking bull world.

Businessman, rancher, bucking bull trainer and CEO of Exclusive Genetics, Billy Jaynes developed a marketing concept six years ago that was based on the horse racing industry.

Jaynes comments that, "The bucking bull industry, since its inception was a closed society of rancher, farmers and cowboys. I saw the opportunity to open investment to mainstream fans through the horse racing model. The vast majority of horse owners are not involved in the maintenance of the animal. They hire a trainer to care for the horse and get the enjoyment and financial rewards of the sport by watching their animal participate in competition. It's the same with owning bucking bulls, EG's operations is setup where an owner does not have to maintain the bull. Both investors and sportsman are finding this style of industry participation to be very appealing and a unique investment."

Investment in the breeding and development of young bulls to compete in 2-year-old futurities is skyrocketing. A Bucking Bull Futurity is a competition held for two year-old bulls that do not have a rider on their back. A mechanical weight is placed on the bulls back and is judged on kick, spin, intensity and the perceived difficulty to ride.

What makes the Million Dollar Bucking Bull Championship all the more interesting and exciting is that the vast amount of bucking bull owners are neither traditional cowboys nor breeders, but mainstream investors who don't possess a hauling trailer or ranch.

Jaynes said that "In the turbulent current world of Wall Street, livestock may provide an additional avenue to seek return." He added, "It's amazing to think that one of our investors who mostly consist of businesspeople, fans and professionals will in just a few months walk away with the $500,000 winner's share of the Million Dollar Bucking Bull Championship purse. We did the training work, now it's time for them to root!"

The Million Dollar Bucking Bull Championship will be held in December during the National Finals Rodeo in Las Vegas with $1,000,000 in prize money. It will offer the largest purse for any bucking bull event in the history of the sport. Investment in the purchase of bulls for the 2013 event was so strong that investors are currently buying into the 2015 edition of the Futurity.

The Million Dollar Bucking Bull Championship and all of EG's Bucking Bull Games have become the third largest event to take place in Las Vegas during the Wrangler National Finals Rodeo, held over a 10 day period each December. EG's Bucking Bulls Games will payout in excess of over $1,300,000 in 2013. Only the National Finals Rodeo and World Series of Team Roping offer larger payouts during that period.

To learn more about Exclusive Genetics' Million Dollar Bucking Bull Championship or other investment opportunities, contact Jeff Bressler at jeff@exclusivegenetics.com or visit http://www.exclusivegenetics.com.

See more here:
Bucking Bull Industry Leader, Exclusive Genetics, Offers Opportunities to Non-Traditional Investors Who Will Reap ...

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) announced today that it will report its third quarter 2013 financial results on Tuesday, November 5, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Tuesday, November 5, 2013

1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

REPLAY access

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The companys lead product, ADCETRIS (brentuximab vedotin), is an ADC that, in collaboration with Millennium: the Takeda Oncology Company, has been approved for two indications in 35 countries, including the U.S., European Union and Canada. Additionally, ADCETRIS is being evaluated broadly in more than 20 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-75, ASG-22ME, SGN-CD19A, SGN-CD33A, SGN-LIV1A and ASG-15ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at http://www.seattlegenetics.com.

More:
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2013 Financial Results on November 5 ...

Recommendation and review posted by Bethany Smith

International Academy of Cardiology: Luisa Mestroni, M.D.: PERSONALIZED MEDICINE IN DILATED
PERSONALIZED MEDICINE IN DILATED CARDIOMYOPATHY Luisa Mestroni, M.D., University of Colorado Cardiovascular Institute, Aurora, CO, USA Presented at the: Inte...

By: cardiologyonline

Read the original here:
International Academy of Cardiology: Luisa Mestroni, M.D.: PERSONALIZED MEDICINE IN DILATED - Video

Recommendation and review posted by sam

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will initiate a pre-clinical study for Multiple Sclerosis (MS) at the Hebrew University Hadassah Medical Centers SPF-grade animal laboratory in Jerusalem. The study was approved by the Institutional Animal Care and Use Committee (IACUC) of the Hebrew University.

Based on promising pre-clinical data published by the Company's Chief Scientist, Prof. Daniel Offen of Tel Aviv University, BrainStorm will conduct further studies using the Experimental Autoimmune Encephalomyelitis (EAE) animal model to evaluate MS as an additional indication for its NurOwn technology. Professor Dimitrios Karussis and Dr. Ibrahim Kassis, who have published extensively on pre-clinical research using the EAE model, will be the Principal Investigators of the study.

Prof. Karussis, a Key Opinion Leader in the field of MS, is Head of the multi-disciplinary MS Clinic and Center at Hadassah, member of the European Steering Committee for Bone Marrow Transplantation in MS, member of the Executive Board and Scientific Committee of the European School of Neuroimmunology (ESNI), and former board member of the European Council and Committee for Treatment and Research in MS. He has been the Principal Investigator of several multi-national clinical trials in MS conducted by global pharmaceutical companies.

About NurOwn

NurOwn is an autologous, adult stem cell therapy technology that induces bone marrow-derived mesenchymal stem cells (MSC) to secrete high levels of neurotrophic factors for protection of existing motor neurons, promotion of motor neuron growth, and re-establishment of nerve-muscle interaction. More information about NurOwn can be found at http://brainstorm-cell.com/index.php/science-a-technology/-nurown.

About Multiple Sclerosis (MS)

Multiple sclerosis (MS) is believed to be an autoimmune disorder that affects the central nervous system (CNS). Autoimmune means that the bodys immune system mistakenly attacks its own tissue, in this case, the tissues of the CNS. With MS, autoimmune damage to neurons disrupts the bodys ability to send and receive signals, thus causing MS-related symptoms.Symptoms may vary due to the location and extent of the damage. Worldwide, MS may affect more than 2 million individuals, including approximately 400,000 people in the United States.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

Go here to see the original:
BrainStorm to Initiate Study for Multiple Sclerosis at Hadassah Medical Center

Recommendation and review posted by simmons

Dublin, Oct. 14, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/bq6p7v/bioinformatics) has announced the addition of the "Global Bioinformatics Market Report 2013-2017" report to their offering.

Based on the use of bioinformatics, the various sectors covered in this report are medicine, agriculture, environment, animal, forensic, academics, and others (homeland security and defense, law-enforcement groups, bio-weapon creation, antibiotic resistance, and evolutionary biotechnology). The medical sector accounted for a lions share of the bioinformatics market in 2012. The medical sector has been further classified as molecular medicine, gene therapy, drug discovery and development, clinical diagnostics, and reproductive biotechnology.

The bioinformatics market, by products and services, has been classified as knowledge management tools, platforms, and services. These segments are integral components of application areas such genomics, proteomics, and other life-science research, and are used for the acquisition, development, management, analysis, and integration of huge amounts of data generated during biological research. Knowledge management tools dominated the bioinformatics market in 2012, followed by platforms and services. Knowledge management tools are majorly used by researchers to handle large volumes of heterogeneous information and to integrate them with existing knowledge repositories.

Segments in the bioinformatics application market are genomics, proteomics, chemoinformatics, molecular phylogenetics, metabolomics, transcriptomics, and others (glycomics, cytomics, physiomics and interactomics). Genomics contributes the highest to the bioinformatics market; it is poised to grow at a high CAGR from 2012 to 2017. The application of bioinformatics in genomics is driven by growing pharmacogenomics applications for the discovery of new drugs and characterization of older drugs, development of new bioinformatics tools to handle large sets of data generated through genomics research, and decreasing cost of DNA sequencing. Metabolomics is the fastest-growing application area due to developments in analytical instruments that enable profiling of metabolites with high throughput and accuracy.

North America accounted for the largest market share of the bioinformatics market, followed by Europe, in 2012. This is attributed by an increasing demand for bioinformatics in genomics and proteomics research, technological advancements, growing use of bioinformatics tools in the drug discovery process, and presence of a large number of market players. However, other regions such as Asian and Latin American countries represent emerging markets, owing to a rise in research outsourcing by pharmaceutical giants, increasing number of Contract Research Organizations (CROs), rise in public and private sector investment, and growing industry -academia partnerships.

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Market Overview

4 Global Bioinformatics Market, By Sectors

Here is the original post:
Global Bioinformatics Market Report 2013-2017

Recommendation and review posted by Bethany Smith

Santa Fe, New Mexico (PRWEB) October 15, 2013

October 15, 2013, Santa Fe, New Mexico

The Estrogen Gene Test Co. and General Genetics Corporation are pleased to announce the launch of a saliva-based test that can identify polymorphisms in all of the key estrogen metabolism genes.

Decades of research from top universities and institutions around the world reveal in studies that while mutations on single estrogen metabolism genes do not seem to raise the risk of breast cancer; women who possess two or more mutations are at greater risk have from a 2.7 to 13 fold increased risk of breast cancer than women without mutations.

80% of all breast cancer diagnosis is to women with no family history. EstroGeneTM allows physicians to pinpoint patients at greater risk and clinically intervene to improve estrogen metabolism function. In turn, this may lower their breast cancer risk regardless of their previous or current estrogen exposure, breast cancer status or fertility stage.

EstroGeneTM is recommended for all women and girls, however critical populations to test include women with past, present or future exposure to estrogen-based medications such as hormone replacement therapy, bio-identical hormones and in-vitro fertilization. Women treated for estrogen positive breast cancer, women with a family history of breast cancer and women with severe peri-menopausal symptoms should also test.

Since the first results of the landmark Womens Health Initiative study published in 2002, which highlighted the two-and-a-half times increased risk of breast cancer to women taking Hormone Replacement Therapy, physicians have struggled with the complexity of relieving menopausal or peri-menopausal symptoms and improving fertility. On the one hand, estrogen based medications may help relieve severe symptoms or promote fertility or allow egg retrieval. On the other hand, breast cancer, as well as other risks, are well known. Physicians no longer need to operate within the 2.5 times increased risk bell curve but can assess each patients risk individually and actively work to mitigate that risk by improving estrogen metabolism function.

Dr. Joseph Veltmann, Ph.D., Chief Scientific Officer for the Estrogen Gene Test Company, Founder of the Institute for Individualized Medicine and one of the worlds leading Nutrigenomic experts has been following 350 high risk women with mutation on the genes in the EstroGeneTM for the past 10 years. Out of the 350 women followed, none have developed the breast cancer disease or had a recurrence by following gene specific protocols to improve estrogen metabolism function. Dr. Veltmann commented, Since the vast majority of women have no family history of breast cancer, the increased availability of this test can allow women to take more meaningful control over their health. It may remove some of the mystery behind a breast cancer diagnosis and its prevention.

The Estrogen Gene Test Company has partnered with Clinical Testing Laboratory, a division of General Genetics Corporation, as its laboratory partner in the processing of Estrogene. Clinical Testing Laboratories is CLIA-certified and performs a wide variety of genetic analysis, including pharmacogenomics, genotyping and other sequencing services for partners around the world.

About Estrogen Gene Test Company The Estrogen Gene Test Co., http://www.estrogengenetest.com, is an outgrowth of the efforts of the Hormonal Cancer Foundation, http://www.hormonalcancer.org, to promote estrogen metabolism genetic testing before, during and after the use of estrogen medications or for women with estrogen receptor positive breast cancer. EGT is strongly committed to genetic testing to prevent breast cancer and is asking all women taking the test to participate in a Hormonal Cancer Foundation longitudinal study examining the outcome of changing gene expression to prevent breast cancer.

Original post:
The Estrogen Gene Test Co. and General Genetics Corporation Announce the Launch of EstroGeneTM, for Breast Cancer ...

Recommendation and review posted by Bethany Smith

Distinguished cardiologist brings extensive experience in novel approaches for treating patients with cardiovascular disease

Raleigh, N.C., Oct. 14, 2013 - INC Research, a therapeutically focused global clinical research organization (CRO) with a Trusted Process for delivering reliable results, today announced the appointment of Martin Sullivan, MD, as Executive Medical Director, Cardiovascular Medicine. Dr. Sullivan will leverage his strong therapeutic insight into clinical trials involving cardiovascular drugs and devices for a wide range of conditions to provide hands-on medical management of the Company`s cardiology trials and to drive clinical development globally in this key therapeutic area.

"The prevalence of cardiovascular diseases provides significant opportunity for the development of new therapies to improve the health and overall wellbeing of many patients worldwide," said Sally Osmond, Executive Vice President and General Manager, Cardiovascular and Endocrinology Clinical Development at INC Research. "Marty is a highly respected cardiologist with extensive experience both in practice and in clinical development, having implemented more than 100 clinical research projects. We`re thrilled to have a thought leader of his caliber to lead development of these complex trials."

Board-certified in both internal medicine and cardiovascular diseases, Dr. Sullivan brings more than 25 years of experience in medical practice and clinical research to INC Research. Prior to joining the Company, he worked as a research consultant specializing in noninvasive cardiology. He earned his medical degree at The Ohio State University and received his post-graduate cardiology training at Duke University where he remained on faculty, later becoming an Associate Professor of Medicine. Dr. Sullivan has had a long and distinguished career at a variety of institutions, including stints as the Director of the Duke Center for Integrative Medicine; Director of Cardiovascular Research at the Heartland Regional Medical Center in St. Joseph`s, Missouri; and a Senior Research Consultant in the Division of Cardiology at the University of North Carolina. For his contributions to cardiovascular research, Dr. Sullivan was named an Established Investigator of the American Heart Association.

Dr. Sullivan will present "New Frontiers in Cardiovascular Research: Biologic Therapies - Using stem cells, gene therapy, and growth factors to treat patients with cardiovascular disease," a complimentary webinar, on Wednesday, Oct. 16, at 3 p.m. GMT/10 a.m. EDT. The webinar will cover the current state of research for cardiovascular diseases and will discuss novel approaches in clinical development, such as cell therapies, growth factors and gene therapies that are being used to regrow cells, repair damage and improve cardiovascular health without surgery. Click here to register.

About INC Research INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit http://www.incresearch.com or follow us at @inc_research.

Contact: Lori Dorer, Media +1 (513) 345-1685

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: INC RESEARCH, LLC via Thomson Reuters ONE HUG#1735540

Original post:
INC Research Strengthens Cardiovascular Research Capabilities with Appointment of Dr. Martin Sullivan as Executive ...

Recommendation and review posted by Bethany Smith

tzi the Iceman has at least 19 living male relatives in the Austrian Tirol, according to a genetic study into the origins of the people who now inhabit the region.

Scientists from the Institute of Legal Medicine at Innsbruck Medical University analyzed DNA samples taken from 3,700 blood donors in the Tyrol region of Austria.

During their study, they discovered that 19 individuals share a particular genetic mutation with the 5,300-year-old mummy, whose full genome was published last year.

PHOTOS: Iceman Mummy 20 Yrs On: Mysteries Remain

These men and the Iceman had the same ancestors, Walther Parson, the forensic scientist who carried out the study, told the Austrian Press Agency.

The researchers focused on parts of the human DNA which are generally inherited unchanged.

In men it is the Y chromosomes and in females the mitochondria. Eventual changes arise due to mutations, which are then inherited further, Parson explained.

People with the same mutations are categorized in haplogroups. Designed with letters, haplogroups allow researchers to trace early migratory routes since they are often associated with defined populations and geographical regions.

Indeed, tzis haplogroup is very rare in Europe.

The Iceman had the halogroup G, sub category G-L91. In our research we found another 19 people with this genetic group and subgroup, Parson said.

Read the original:
Living Relatives of Iceman Mummy Found

Recommendation and review posted by Bethany Smith

Why Science? Plant Genetics
Explore Research at the University of Florida: Matias Kirst, an associate professor in quantitative genetics at the University of Florida, discusses how his ...

By: FloridaMuseum

Visit link:
Why Science? Plant Genetics - Video

Recommendation and review posted by Bethany Smith